ArticleCell reports methods2026
A protein surface-aware multimodal framework for residue-level metal-binding site recognition.
Article in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate identification of metal-binding sites is essential for elucidating metalloprotein functions in cellular processes. Here, we introduce MetalBind, a protein surface-aware, multimodal deep learning framework tailored for residue-level recognition of metal-binding sites across diverse biologically relevant metals. By integrating advanced protein sequence embeddings, atom-specific physicochemical features, and a geometry-informed surface point learning module, MetalBind achieves higher predictive accuracy than existing methods. Our benchmarks across 13 metal-specific datasets reveal MetalBind's superior performance in several metrics. Notably, its efficacy persists even with sparse training data, highlighting its potential for large-scale metalloproteome annotation and guiding the rational design of engineered metalloproteins. These advancements significantly enhance metalloproteome annotation capabilities and expedite functional metalloprotein discovery. To promote accessibility, an online implementation of MetalBind is publicly available for the research community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.